Question- the combo trials are shorter in duration and involve lower n values. Is that enough to allow the docs to prescribe said combos to patients until such time larger combo trials are conducted for GBM? I can see piggybacking off the phase 3 and other numerous small trials as a testament to being very safe. In addition, these small trials are yielding excellent p values reducing any potential value derived from additional larger follow up studies. Therefore, additional time consuming larger n value follow up combo studies may not be necessary in the context of RA regulatory hurdles. Thoughts?
Market Data 
Markets 
AI
